Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
Go back to Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)| (NASDAQ: SRRK) | Delayed: 47.67 -1.81 (3.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.48 | 52 Week High | $ | |||
| Open | $49.71 | 52 Week Low | $ | |||
| Day High | $49.95 | P/E | N/A | |||
| Day Low | $47.54 | EPS | $ | |||
| Volume | 838,705 | |||||
